Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs). Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Vitale, Nuzzo Pier
  • Pond, Gregory
  • Abou Alaiwi, Sarah
  • Nassar, Amin
  • Flippot, Ronan
  • Choueiri, Toni K
  • Harshman, Lauren Christine
  • Sonpavde, Guru

publication date

  • May 20, 2019